With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.129799-08-2,1-tert-Butyl 3-methyl piperazine-1,3-dicarboxylate,as a common compound, the synthetic route is as follows.
To a 50 mL of sealing tube were added 1-tert-butyl 3-methyl piperazine-1,3-dicarboxylate (500 mg, 2.05 mmol) , iodomethane (580mg, 4.10 mmol) , potassium carbonate (424 mg, 3.07 mmol) and acetone (10 mL) .The mixture was stirred at 50 for 6 h and concentrated. The residue was diluted withwater (20 mL) . The resulting mixture was extracted with DCM (10 mL ¡Á 3) . The combined organic layers were dried over anhydrous Na2SO4and concentrated to give 1-tert-butyl 3-methyl 4-methylpiperazine-1,3-dicarboxylate as a light yellow solid (290 mg, 54) . 1H NMR (400 MHz, CDCl3): delta ppm 4.65-4.83 (m, 1H) , 4.29-4.33 (m, 1H) , 4.18-4.23 (m, 1H) , 4.05-4.11(m, 1H) , 3.80-3.94 (m, 3H) , 3.88 (s, 3H) , 3.66 (s, 3H) , 1.48 (s, 9H) and MS-ESI: m/z 259.30 [M+H] +.
129799-08-2, As the paragraph descriping shows that 129799-08-2 is playing an increasingly important role.
Reference£º
Patent; SUNSHINE LAKE PHARMA CO., LTD.; ZHANG, Yingjun; LIU, Bing; YU, Tianzhu; ZHANG, Xiangyu; ZHANG, Shiguo; ZHANG, Jiancun; CHENG, Changchung; (426 pag.)WO2016/34134; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics